Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

As of July 1, CVS dropped Zepbound from preferred coverage for those covered by its pharmacy benefit manager, Caremark. Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the ...

But a recent coverage change by a major pharmacy benefit manager may force many to decide how much they're willing to pay for the drug or whether they want to try another weight loss option. As of ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

Zepbound users face new hurdles as CVS drops the drug Eli Lilly's Zepbound faces insurance hurdles as coverage changes could spike out-of-pocket costs for millions relying on weight loss medications.